LivaNova PLC
LIVN
Rank in Stocks
#3860
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Share Price
$78.25
Market Cap
$4.30B
Change (1 day)
-1.84%
Change (1 year)
43.02%
Country
GB
Trade LivaNova PLC (LIVN)
Category
Healthcare
Revenue for LivaNova PLC (LIVN)
Revenue in Jun 2026 TTM: $1.47B
According to LivaNova PLC latest financial reports the company's current revenue (TTM) is $1.47B. In 2023 the company made a revenue of $1.15B an increase over the revenue in the year 2022 that was $1.02B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for LivaNova PLC from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.47B | 17.40% |
| 2024 | $1.25B | 8.66% |
| 2023 | $1.15B | 12.89% |
| 2022 | $1.02B | -1.31% |
| 2021 | $1.04B | 10.82% |
| 2020 | $934.24M | -13.83% |
| 2019 | $1.08B | -2.06% |
| 2018 | $1.11B | 9.35% |
| 2017 | $1.01B | -16.61% |
| 2016 | $1.21B | 316.35% |
| 2015 | $291.56M | 3.38% |
| 2014 | $282.01M | 10.89% |
| 2013 | $254.32M | 16.39% |
| 2012 | $218.50M | 14.72% |
| 2011 | $190.46M | 13.52% |
| 2010 | $167.78M | 16.83% |
| 2009 | $143.60M | 18.45% |
| 2008 | $121.23M | -7.44% |
| 2007 | $130.97M | 6.10% |
| 2006 | $123.44M | 19.33% |
| 2005 | $103.44M | -6.57% |
| 2004 | $110.72M | 5.99% |
| 2003 | $104.47M | 49.00% |
| 2002 | $70.11M | 46.40% |
| 2000 | $47.89M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $46.59B | 3,065.79% |
US
|
|
| $35.48B | 2,311.40% |
IE
|
|
| $25.84B | 1,655.81% |
US
|
|
| $21.00B | 1,326.83% |
US
|
|
| - | - |
DE
|
